The company stated that although it has dropped vobra duo, it remains optimistic about its other candidate MGC026.

MacroGenics argues that margetuximab works by tweaking the “Fc” part of Herceptin – the tail of the ‘Y’ shaped antibody – so that it interacts more efficiently with the immune system ...

MacroGenics' valuation has declined due to ... like the CD123-targeted DART molecule MGD024, the B7-H3 novel ADC MGC026 in phase 1 study, and MGC028, an ADAM9 ADC set to move into the clinic ...

MacroGenics has a strong cash position ... three molecules with our three core platforms, our FC engineered, our DART bispecific and our ADC platform are being pursued for treatments for various ...

March 20, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ ... tetravalent PD-1 × CTLA-4 DART® molecule designed to enhance CTLA-4 blockade on dual-expressing, tumor-infiltrating lymphocytes ...

We will begin the MacroGenics fourth quarter and full year ... our bispecific tetravalent DART molecule designed to enable blockade of PD-1 and CTLA-4 with potentially enhanced CTLA-4 blockade ...